NEW YORK (GenomeWeb News) – EraGen Biosciences said today that it has formed a strategic partnership with Illumina to develop high-throughput, multiplexed clinical assays.
Under the agreement, EraGen, based in Madison, Wis., has non-exclusively licensed the use of Illumina's BeadXpress platform to develop and commercialize molecular-based, high-throughput, clinical assays using EraGen's MultiCode-PLx technology.
Meantime, Illumina has non-exclusively licensed EraGen's MultiCode-PLx technology for the life sciences, research, and clinical markets.
Financial terms of the agreement were not disclosed.
"Our newly formed relationship with Illumina further validates our MultiCode technology's versatile application in the development and commercialization of molecular-based assays for the clinical market," Irene Hrusovsky, president and CEO of EraGen, said in a statement.
EraGen's MultiCode technology detects RNA and DNA targets by combining multiplexed PCR with its ISO bases, which are structurally similar to standard nucleobases but have altered base-pairing specificity.
EraGen said that the pact is part of its strategy to continue expanding its commercial efforts in the molecular diagnostics market.